Valeant Pharmaceuticals International Inc (VRX.TO)
VRX.TO on Toronto Stock Exchange
21.94CAD
20 Apr 2018
21.94CAD
20 Apr 2018
Change (% chg)
$0.00 (+0.00%)
$0.00 (+0.00%)
Prev Close
$21.94
$21.94
Open
$21.88
$21.88
Day's High
$22.13
$22.13
Day's Low
$21.62
$21.62
Volume
615,269
615,269
Avg. Vol
1,851,486
1,851,486
52-wk High
$30.56
$30.56
52-wk Low
$11.20
$11.20
Revenue & Earnings Per Share
Consensus Estimates Analysis
| # of Estimates | Mean | High | Low | 1 Year Ago | |
|---|---|---|---|---|---|
| SALES (in millions) | |||||
| Quarter Ending Jun-18 | 15 | 2,041.57 | 2,113.00 | 1,882.70 | 2,167.10 |
| Quarter Ending Sep-18 | 15 | 2,100.89 | 2,159.80 | 2,048.90 | 2,187.20 |
| Year Ending Dec-18 | 20 | 8,236.50 | 8,446.00 | 8,111.80 | 8,909.04 |
| Year Ending Dec-19 | 18 | 8,323.80 | 8,605.00 | 8,054.30 | 8,969.11 |
| Earnings (per share) | |||||
| Quarter Ending Jun-18 | 14 | 0.75 | 0.87 | 0.66 | 0.95 |
| Quarter Ending Sep-18 | 15 | 0.65 | 0.93 | -2.04 | 1.19 |
| Year Ending Dec-18 | 18 | 3.13 | 4.05 | 2.69 | 4.67 |
| Year Ending Dec-19 | 17 | 3.39 | 4.06 | 2.74 | 5.04 |
| LT Growth Rate (%) | 3 | -4.81 | 0.88 | -13.30 | 16.90 |
Sales and Profit Figures in US Dollar (USD);
Valuation Ratios
| Company | industry | sector | ||
|---|---|---|---|---|
| P/E Ratio (TTM) | 4.22 | 31.01 | 33.60 | |
| P/E High - Last 5 Yrs. | 55.49 | 40.51 | 45.95 | |
| P/E Low - Last 5 Yrs. | 5.12 | 24.14 | 24.93 | |
| Beta | -0.34 | 0.82 | 0.80 | |
| Price to Sales (TTM) | 0.69 | 4.52 | 7.07 | |
| Price to Book (MRQ) | 1.02 | 4.11 | 5.13 | |
| Price to Tangible Book (MRQ) | -- | 4.99 | 6.73 | |
| Price to Cash Flow (TTM) | 1.40 | 22.60 | 25.52 | |
| % Owned Institutions | 66.84 | 1.16 | 2.22 | |
Dividends
| Company | industry | sector | ||
|---|---|---|---|---|
| Dividend Yield | -- | 1.61 | 1.51 | |
| Dividend Yield - 5 Year Avg | -- | 0.72 | 0.75 | |
| Dividend 5 Year Growth Rate | -- | 2.72 | 3.93 | |
| Payout Ratio(TTM) | 0.00 | 20.12 | 20.35 | |
Growth Rates
| Company | industry | sector | ||
|---|---|---|---|---|
| Sales (MRQ) vs Qtr. 1 Yr. Ago | -9.97 | 6.90 | 9.02 | |
| Sales (TTM) vs TTM 1 Yr. Ago | -9.82 | 9.71 | 10.83 | |
| Sales - 5 Yr. Growth Rate | 20.18 | 7.67 | 8.21 | |
| EPS (MRQ) vs Qtr. 1 Yr. Ago | 11.06 | 19.14 | 22.25 | |
| EPS (TTM) vs TTM 1 Yr. Ago | 158.80 | -- | -- | |
| EPS - 5 Yr. Growth Rate | -- | 8.96 | 10.26 | |
| Capital Spending - 5 Yr. Growth Rate | 13.16 | 9.66 | 10.37 | |
Financial Strength
| Company | industry | sector | |
|---|---|---|---|
| Quick Ratio (MRQ) | 0.87 | 2.53 | 2.53 |
| Current Ratio (MRQ) | 1.11 | 3.62 | 3.62 |
| LT Debt to Equity (MRQ) | 431.44 | 8.61 | 11.31 |
| Total Debt to Equity (MRQ) | 450.49 | 10.92 | 13.97 |
| Interest Coverage (TTM) | 0.58 | 35.68 | 30.11 |
Profitability Ratios
| Company | industry | sector | ||
|---|---|---|---|---|
| Gross Margin (TTM) | 70.79 | 54.62 | 54.01 | |
| Gross Margin - 5 Yr. Avg. | 72.24 | 52.07 | 52.12 | |
| EBITD Margin (TTM) | 37.85 | -- | -- | |
| EBITD - 5 Yr. Avg | 45.10 | 18.40 | 15.89 | |
| Operating Margin (TTM) | -0.23 | 12.92 | 4.33 | |
| Operating Margin - 5 Yr. Avg. | 5.41 | 14.20 | 11.25 | |
| Pre-Tax Margin (TTM) | -19.96 | 13.17 | 4.97 | |
| Pre-Tax Margin - 5 Yr. Avg. | -10.72 | 14.56 | 11.56 | |
| Net Profit Margin (TTM) | 16.38 | 9.57 | 1.58 | |
| Net Profit Margin - 5 Yr. Avg. | -2.92 | 10.88 | 7.89 | |
| Effective Tax Rate (TTM) | -- | 22.52 | 31.30 | |
| Effective Tax Rate - 5 Yr. Avg. | -- | 23.67 | 24.27 | |
Efficiency
| Company | industry | sector | ||
|---|---|---|---|---|
| Revenue/Employee (TTM) | 421,449 | 922,802,967 | 816,988,634 | |
| Net Income/Employee (TTM) | 69,034 | 108,527,563 | 96,050,323 | |
| Receivable Turnover (TTM) | 3.75 | 5.62 | 5.56 | |
| Inventory Turnover (TTM) | 2.42 | 2.56 | 3.45 | |
| Asset Turnover (TTM) | 0.22 | 0.92 | 0.89 | |
Management Effectiveness
| Company | industry | sector | ||
|---|---|---|---|---|
| Return on Assets (TTM) | 3.53 | 10.96 | 10.54 | |
| Return on Assets - 5 Yr. Avg. | -0.72 | 12.17 | 11.56 | |
| Return on Investment (TTM) | 3.92 | 13.60 | 13.19 | |
| Return on Investment - 5 Yr. Avg. | -0.80 | 15.72 | 14.97 | |
| Return on Equity (TTM) | 31.75 | 15.26 | 15.00 | |
| Return on Equity - 5 Yr. Avg. | -5.19 | 16.89 | 16.25 | |
| 1 Year | 3 Year | 5 Year | |
|---|---|---|---|
| Sales % | -9.82 | 2.06 | 20.18 |
| EPS (TTM) % | 158.56 | 16.35 | -- |
| Dividend % | -- | -- | -- |
Note: Units in Millions of US Dollars
Performance for Valeant Pharmaceuticals International Inc
| Period | % Actual |
% vs. S&P 500 |
Rank In Industry |
Industry Rank |
|---|---|---|---|---|
| 4 Week | 11.78 | 8.35 | 99 | 70 |
| 13 Week | -20.17 | -15.98 | 99 | 46 |
| 26 Week | 41.63 | 36.60 | 99 | 21 |
| 52 Week | 93.47 | 70.70 | 99 | 21 |
| YTD | -17.32 | -17.22 | 99 | 31 |
Note:: Rank is a percentile that ranges from 0 to 99, with 99 = best.
- BRIEF-U.S. International Trade Commission Says Will Probe Certain Clidinium Bromide-Containing Products After Valeant Pharmaceuticals Filed Complaint -Statement
- Canada seeks U.S. help to solve EpiPen shortage
- UPDATE 3-Canada seeks U.S. help to solve EpiPen shortage
- BRIEF-Valeant To Purchase Up To $1.5 Bln Aggregate Principal Of Outstanding Notes
- BRIEF-Valeant Says Joseph Papa's 2017 Total Compensation $4.9 Mln
Institutional Holders
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.